Logo image of BNR

BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Fundamental Analysis

USA - NASDAQ:BNR - US12233L2060 - ADR

8.36 USD
-0.22 (-2.56%)
Last: 10/10/2025, 9:12:54 PM
Fundamental Rating

2

Overall BNR gets a fundamental rating of 2 out of 10. We evaluated BNR against 536 industry peers in the Biotechnology industry. BNR has a bad profitability rating. Also its financial health evaluation is rather negative. BNR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BNR had negative earnings in the past year.
In the past year BNR has reported a negative cash flow from operations.
BNR had negative earnings in each of the past 5 years.
BNR had a negative operating cash flow in each of the past 5 years.
BNR Yearly Net Income VS EBIT VS OCF VS FCFBNR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

The Return On Assets of BNR (-17.00%) is better than 79.48% of its industry peers.
BNR has a Return On Equity of -24.86%. This is amongst the best in the industry. BNR outperforms 81.16% of its industry peers.
Industry RankSector Rank
ROA -17%
ROE -24.86%
ROIC N/A
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
BNR Yearly ROA, ROE, ROICBNR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

Looking at the Gross Margin, with a value of 72.12%, BNR belongs to the top of the industry, outperforming 82.46% of the companies in the same industry.
BNR's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BNR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
BNR Yearly Profit, Operating, Gross MarginsBNR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BNR has about the same amount of shares outstanding.
The number of shares outstanding for BNR has been increased compared to 5 years ago.
BNR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BNR Yearly Shares OutstandingBNR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BNR Yearly Total Debt VS Total AssetsBNR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of -4.78, we must say that BNR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.78, BNR is not doing good in the industry: 60.82% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that BNR is not too dependend on debt financing.
BNR's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. BNR outperforms 47.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.78
ROIC/WACCN/A
WACC8.32%
BNR Yearly LT Debt VS Equity VS FCFBNR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

A Current Ratio of 3.22 indicates that BNR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.22, BNR is doing worse than 61.75% of the companies in the same industry.
A Quick Ratio of 2.97 indicates that BNR has no problem at all paying its short term obligations.
BNR has a worse Quick ratio (2.97) than 62.13% of its industry peers.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 2.97
BNR Yearly Current Assets VS Current LiabilitesBNR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 96.17% over the past year.
Looking at the last year, BNR shows a small growth in Revenue. The Revenue has grown by 5.20% in the last year.
The Revenue has been growing slightly by 6.21% on average over the past years.
EPS 1Y (TTM)96.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.44%
Revenue 1Y (TTM)5.2%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%9.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 15.51% on average over the next years. This is quite good.
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BNR Yearly Revenue VS EstimatesBNR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
BNR Yearly EPS VS EstimatesBNR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BNR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNR Price Earnings VS Forward Price EarningsBNR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNR Per share dataBNR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BNR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURNING ROCK BIOTECH LTD-ADR

NASDAQ:BNR (10/10/2025, 9:12:54 PM)

8.36

-0.22 (-2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-08 2025-09-08
Earnings (Next)12-02 2025-12-02
Inst Owners30.6%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap85.76M
Analysts80
Price TargetN/A
Short Float %0.61%
Short Ratio0.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.14
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-1.99
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS7.34
BVpS7.72
TBVpS7.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17%
ROE -24.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.12%
FCFM N/A
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
F-Score5
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.22
Quick Ratio 2.97
Altman-Z -4.78
F-Score5
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)26.43%
Cap/Depr(5y)152.99%
Cap/Sales(3y)5.44%
Cap/Sales(5y)15.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.44%
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.2%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%9.61%
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%
EBIT growth 1Y80.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y80%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80%
OCF growth 3YN/A
OCF growth 5YN/A